ArticleWiener klinische Wochenschrift2015

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer.

Dominik Riss et al.PubMed ↗Publisher ↗

No numbers read from the abstract.